Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ⅰ-Ⅱa Clinical Study of Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome

NCT06967038 is registered in ClinicalTrials.gov with Bangdong Gong as lead sponsor.

NCT NCT06967038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06967038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ⅰ-Ⅱa Clinical Study of Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome
Lead sponsor
Bangdong Gong
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 28, 2025
Completion date
October 31, 2027
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, primary sjogren's syndrome